Zynerba Pharmaceuticals (ZYNE) News Today → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free ZYNE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative October 31, 2023 | finance.yahoo.comHarmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsOctober 13, 2023 | fool.comWhy Shares of Harmony Bioscience Are Falling on FridayOctober 11, 2023 | markets.businessinsider.comNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesOctober 11, 2023 | finance.yahoo.comHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEOctober 11, 2023 | marketbeat.comTrading was temporarily halted for "ZYNE" at 07:10 PM with a stated reason of "News pending."October 4, 2023 | finance.yahoo.comImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsSeptember 29, 2023 | finance.yahoo.com20 Countries With Highest Rate of EpilepsySeptember 29, 2023 | finance.yahoo.comZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023September 27, 2023 | bizjournals.comHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealSeptember 27, 2023 | marketbeat.comTrading was temporarily halted for "ZYNE" at 07:09 PM with a stated reason of "News pending."September 14, 2023 | finance.yahoo.comInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals IncSeptember 14, 2023 | finance.yahoo.comZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research SymposiumAugust 16, 2023 | msn.comHC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)August 15, 2023 | finance.yahoo.comIs Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?August 14, 2023 | marketwatch.comZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEAugust 14, 2023 | markets.businessinsider.comCrude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike HigherAugust 14, 2023 | technews.tmcnet.comZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 14, 2023 | finance.yahoo.comHARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.August 14, 2023 | marketbeat.comTrading was temporarily halted for "ZYNE" at 07:08 AM with a stated reason of "News pending."July 25, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces New Date for Reconvened Annual MeetingJune 29, 2023 | finance.yahoo.comZynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?June 28, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Further Adjournment of Annual MeetingJune 20, 2023 | finance.yahoo.comZynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual ConferenceJune 13, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Partial Adjournment of Annual MeetingMay 17, 2023 | bizjournals.comMain Line CBD drug developer plans reverse stock split to boost share priceMay 15, 2023 | finanznachrichten.deZynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsMay 15, 2023 | investing.comZynerba Pharma (ZYNE) Earnings Dates & ReportsMay 15, 2023 | msn.comZynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The DetailsMay 15, 2023 | finance.yahoo.comZynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsMay 15, 2023 | finance.yahoo.comZynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsApril 18, 2023 | marketwatch.comFibromyalgia Treatment Drug Market Overview and Scope By 2030April 14, 2023 | marketwatch.comZynerba Pharmaceuticals Presents Data on Zygel(TM) at the 55th Gatlinburg ConferenceApril 12, 2023 | finance.yahoo.comZynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg ConferenceApril 5, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg ConferenceMarch 28, 2023 | finanznachrichten.deZynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsMarch 28, 2023 | benzinga.comZynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?March 28, 2023 | finance.yahoo.comZynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsMarch 14, 2023 | finanznachrichten.deZynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley BankMarch 13, 2023 | finance.yahoo.comZynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley BankMarch 7, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN) and Armata Pharmaceuticals (ARMP)March 7, 2023 | finance.yahoo.comZynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 1, 2023 | finance.yahoo.comZynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care ConferenceFebruary 21, 2023 | marketwatch.comFibromyalgia Treatment Drug Market Outlook 2023 and Forecast to 2028 with Top Countries DataFebruary 13, 2023 | marketwatch.com2023, Pain Management Drugs Market to Experience a Significant Increase in Revenues by 2027January 27, 2023 | marketwatch.comFibromyalgia Treatment Drug Market 2023 : Profiling Key Players, Value Estimation and Analysis by Recent Trends to 2028January 12, 2023 | msn.comWhat's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New PaperJanuary 11, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X SyndromeJanuary 10, 2023 | forbes.comZynerba PharmaceuticalsDecember 21, 2022 | proactiveinvestors.comZynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndromeDecember 21, 2022 | finance.yahoo.comZynerba Pharmaceuticals delays data on genetic disorder drug study Get Zynerba Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”. You just have to make this simple move before July 30, 2024. ZYNE Media Mentions By Week ZYNE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZYNE News Sentiment▼0.000.76▲Average Medical News Sentiment ZYNE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZYNE Articles This Week▼01▲ZYNE Articles Average Week Get Zynerba Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LABP News CKPT News MNOV News LTRN News MRNS News LVTX News DERM News RLYB News VHAQ News TPST News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZYNE) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsLEAKED: Jeff Bezos' $330 Million GambleBehind the MarketsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
